RCRune Häckert Christensen

Rune Häckert Christensen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rune Häckert Christensen has a total of 121 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Magnitude and Determinants of Placebo Response in Acute Migraine Trials

    by Luana Miyahira Makita, Eric Katsuyama, Rune Hackert Christensen, Takao Takeshima, Sait Ashina, Elcio Juliato Piovesan, Antonio Medina Luna, Giovanna Nina Ueda, Vanio Do Livramento Junior Antunes, Oguz Kagan Sahin, et al.

  • Open Access

    Depressive and anxiety symptoms during CGRP-targeted migraine prevention: A systematic review and meta-analysis

    by Zainab Al-Sayegh, Sarra Al-Khazali, Haidar M. Al-Khazali, Rune H. Christensen, Poul Videbech, Richard B. Lipton, Henrik W. Schytz

    Background: Migraine is frequently comorbid with depression and anxiety, conditions that amplify disease burden and may impair preventive treatment response. Calcitonin gene-related peptide (CGRP)-targeted therapies have demonstrated robust efficacy in reducing migraine frequency, with emerging evidence suggesting concurrent improvements in psychiatric symptom burden. However, findings derive from heterogeneous study designs and outcome instruments, limiting conclusions regarding consistency and magnitude of these effects. Methods: We conducted a systematic review and meta-analysis of studies reporting changes in depressive and anxiety symptoms in adults with migraine receiving CGRP-targeted preventive therapies. PubMed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), and PsycINFO were searched from inception through July 2026. Eligible studies included randomised controlled trials, post hoc analyses, and real-world observational studies reporting validated self-report or clinician-rated symptom measures at baseline and follow-up. Risk of bias was assessed using the Jadad Scale for randomised trials and the Newcastle-Ottawa Scale for observational studies. Standardised mean differences with 95% confidence intervals were calculated using random-effects models. Results: Twelve studies (n = 3603; 63% female) published between 2020 and 2026 met eligibility criteria, of which nine contributed to quantitative synthesis. Pooled analyses demonstrated consistent reductions in depressive symptoms across instruments at 3 months: Hospital Anxiety and Depression Scale – Depression subscale −1.35 points (95% CI, −1.63 to −1.07), Hamilton Depression Rating Scale −3.73 points (95% CI, −5.76 to −1.71), and Beck Depression Inventory −3.70 points (95% CI, −4.92 to −2.48). Anxiety outcomes improved similarly: Hospital Anxiety and Depression Scale – Anxiety subscale −1.50 points (95% CI, −2.45 to −0.55), Hamilton Anxiety Rating Scale −1.64 points (95% CI, −3.21 to −0.07), and Beck Anxiety Inventory −4.36 points (95% CI, −5.24 to −3.48). In the single placebo-controlled subgroup analysis, fremanezumab was numerically superior to placebo for depressive outcomes, though this difference did not reach statistical significance. Conclusions: CGRP-targeted therapies were consistently associated with reductions in depressive and anxiety symptom scores across multiple validated instruments, with improvements appearing to correlate with effective migraine control, although current study designs cannot differentiate between direct and indirect effects on psychiatric symptoms. Placebo-controlled evidence remains insufficient to draw firm conclusions, and adequately powered randomized controlled trials with psychiatric outcomes as prespecified endpoints are warranted before the nature and magnitude of these effects can be definitively characterized.


  • Open Access

    Blood levels of PACAP in migraine: A systematic review

    by Pil L. Jørgensen, Sarra Al-Khazali, Rune Häckert Christensen, Haidar M. Al-Khazali, Messoud Ashina, Håkan Ashina

    Objective: To examine whether plasma or serum pituitary adenylate cyclase-activating polypeptide (PACAP) levels differ between people with migraine and healthy controls (HCs), and to assess evidence for dynamic alterations during migraine attacks. Methods: A systematic literature search was conducted in PubMed and Embase from inception to December 19, 2025. Eligible studies measured PACAP in plasma or serum of adult or pediatric participants with migraine and reported comparisons with HCs, and/or between ictal and interictal phases. Two reviewers independently screened articles, extracted data, and assessed risk of bias using the QUADAS-2 tool. Results: Eleven studies met the inclusion criteria, comprising seven adult and four pediatric studies. Findings were inconsistent across studies, with some reporting higher PACAP-38 levels in participants with migraine, while others found no differences or even lower levels compared with HCs. Five studies compared ictal and interictal levels, but results were incongruent and lacked intraindividual measurements. Furthermore, all studies were judged to be at high overall risk of bias, primarily due to limitations in participant selection and index test methodology. Conclusions: Current evidence on plasma or serum PACAP-38 levels in migraine is limited and inconsistent. The lack of intraindividual ictal-interictal comparisons and variability in study design and assays further weaken conclusions. Standardized, high-quality studies are essential to resolve existing uncertainties. Trial Registration: The study protocol was prospectively registered in PROSPERO (CRD42024601373).

  • Magnitude and Determinants of Placebo Response in Acute Migraine Trials

    by Luana Miyahira Makita, Eric Katsuyama, Rune Häckert Christensen, Takao Takeshima, Sait Ashina, Elcio Juliato Piovesan, Antonio Medina Luna, Giovanna Nina Ueda, Vanio Do Livramento Junior Antunes, Oguz Kagan Sahin, et al.

    Background and ObjectivesMigraine is a highly prevalent and disabling neurologic disorder. Beyond drug-specific mechanisms, the role of contextual, individual-related, and disease-related factors r...


  • Open Access

    Association of Serum hs‐ CRP and TNF ‐α With Therapeutic Response to Erenumab for Migraine Prevention: A Registry for Migraine ( REFORM ) Study

    by William K. Karlsson, Rune H. Christensen, Haidar M. Al‐Khazali, Dorte A. Olsen, Jonna S. Madsen, Messoud Ashina, Håkan Ashina

    Background: Experimental studies show inflammatory cytokines can modulate calcitonin gene‐related peptide (CGRP) signaling, suggesting systemic inflammatory markers might reflect biological processes relevant to anti‐CGRP therapies. We aimed to determine whether serum high‐sensitivity C‐reactive protein (hs‐CRP) and tumor necrosis factor‐alpha (TNF‐α) are associated with erenumab response in adults with migraine and assess longitudinal biomarker changes during and after treatment. Methods: In this prospective, observational single‐center study, adults with episodic or chronic migraine self‐administered 140 mg erenumab subcutaneously every 4 weeks for 24 weeks. Serum was collected at baseline, Week 24 (end of treatment), and Week 48 (24 weeks post‐treatment). Treatment response was defined as a ≥ 50% reduction in monthly migraine days from baseline to Weeks 13–24. Logistic and linear regression models evaluated associations between baseline biomarkers and response, while longitudinal changes were analyzed using linear mixed‐effects models. Results: Of 679 enrolled participants, serum was analyzed in 623. Among 541 with sufficient data to determine response, 281 (51.9%) were responders. Neither baseline hs‐CRP (OR 1.04; 95% CI 0.96–1.12; p = 0.30) nor TNF‐α (OR 0.75; 95% CI 0.49–1.16; p = 0.20) predicted treatment response. TNF‐α increased from baseline to Week 24 (mean rise 3.0%; 95% CI 0.5%–5.4%; p = 0.030), but no responder–non‐responder differences were found. Conclusions: Peripheral inflammatory biomarkers such as hs‐CRP and TNF‐α neither predict response nor change meaningfully during CGRP‐receptor blockade. These results suggest broadly applied inflammatory markers do not capture treatment‐relevant biology and highlight the need for mechanism‐specific biomarkers to advance personalized migraine therapy.

  • Top Cited Papers
    Open Access

    Plasma CGRP Levels in Migraine

    by William Kristian Karlsson, Rune Häckert Christensen, Haidar M. Al-Khazali, Kristian Agmund Haanes, Niklas Rye Jørgensen, Messoud Ashina, Håkan Ashina

    Calcitonin gene-related peptide (CGRP) plays a central mechanistic role in migraine and is an established drug target. However, it remains unclear whether peripheral plasma CGRP levels meaningfully reflect disease activity. We investigated whether circulating plasma CGRP differs between individuals with migraine and healthy controls and whether concentrations vary across migraine subtypes, clinical status, and preventive treatment use. This cross-sectional observational study enrolled adults (≥18 years) with migraine with aura, migraine without aura, or chronic migraine primarily from specialized care. Healthy controls without personal or first-degree family history of primary headache disorders were mainly recruited through web-based advertisement. Venous blood was obtained by antecubital phlebotomy, and plasma CGRP was quantified in duplicate using a validated high-affinity radioimmunoassay. Controls were matched 1:4 to participants with migraine on age, sex, body mass index, and storage duration. The primary outcome was between-group difference in plasma CGRP concentrations. Group comparisons were performed using Mann-Whitney U tests. Regression models were performed to assess associations with clinical variables. A total of 588 participants with migraine and 147 matched controls were analyzed (mean age 43.1 ± 11.9 vs 41.5 ± 11.5 years; 88.8% vs 85.7% female). The median (interquartile range) plasma CGRP concentrations were lower in participants with migraine compared with controls (125 [68-173] vs 151 [118-199] pmol/L; p < 0.001). Subgroup analyses revealed no significant differences across subtypes (episodic vs chronic, with aura vs without aura), ictal vs interictal status, or preventive medication use (all p > 0.05). Sensitivity analyses restricted to headache-free participants confirmed the principal findings, demonstrating lower plasma CGRP concentrations across all migraine subgroups compared with controls (all p < 0.001). Multivariable models identified no clinical predictors of plasma CGRP levels. Sample storage duration did not correlate with measured levels (Spearman ρ = -0.032; p = 0.37). Plasma CGRP concentrations were modestly lower in migraine and did not vary by clinical subtype or disease state. These findings challenge the assumption that migraine is characterized by elevated circulating CGRP and suggest limited utility of plasma CGRP as a disease biomarker.


  • Open Access

    Magnetic resonance spectroscopy during migraine attacks: A systematic review

    by Delia-Ioana Radutiu, Edina Szabo, Rune Häckert Christensen, Eva-Maria Ratai, Nouchine Hadjikhani, Haidar Muhsen Al-Khazali, Messoud Ashina, Håkan Ashina

    Background: The neurobiological basis of migraine remains incompletely understood. Magnetic resonance spectroscopy (MRS) allows non-invasive quantification of neurochemical and metabolic patterns in the brain, offering unique insights into biochemical processes during distinct migraine phases. This systematic review provides a critical appraisal of existing evidence describing MRS-derived neurochemical and metabolic alterations during spontaneous and experimentally provoked migraine attacks. Methods: A systematic review was conducted in accordance with the PRISMA statement and prospectively registered in PROSPERO. Comprehensive searches of PubMed, Embase, and Scopus were performed from database inception through August 1, 2025. Eligible studies included observational or interventional investigations acquiring 1 H-MRS or 31 P-MRS data during the ictal phase in adults with migraine, incorporating either non-ictal comparisons or healthy controls. Considerable variability in study design, brain regions, and metabolite outcomes precluded quantitative synthesis, necessitating a structured qualitative analysis organized by MRS technique and anatomical region. Results: Eight studies published between 1988 and 2022 met inclusion criteria, comprising five 1 H-MRS investigations and three 31 P-MRS studies, some of which derived from overlapping participant cohorts. Brain regions examined included occipital cortex, pons, frontal cortex, basal ganglia, and parieto-occipital areas. In individual 1 H-MRS studies, occipital cortex analyses demonstrated ictal elevations in total choline and total N-acetyl aspartate, while lower glutathione concentrations were observed. A single 1 H-MRS study targeting the pons identified ictal increases in total creatine and total N-acetyl aspartate. Findings from 31 P-MRS studies indicated altered cerebral energy metabolism during migraine attacks. Conclusions: Available MRS evidence suggests that migraine attacks are associated with altered cerebral energy metabolism, particularly within visual cortical and brainstem regions. However, existing studies differ substantially in design, acquisition parameters, regions of interest, and analytical approaches, such that few directly address comparable questions. Thus, the reproducibility of reported findings remains uncertain. Establishing reliable attack-related metabolic signatures will require well-designed longitudinal MRS investigations capable of directly probing ictal dynamics.

  • Open Access

    Molecular triggers of migraine aura: A systematic review of human pharmacological provocation studies

    by Zahra Hakimzadeh, Basit Ali Chaudhry, Haidar M. Al-Khazali, Rune Häckert Christensen, Messoud Ashina, Håkan Ashina

    Background: Migraine aura reflects transient neurological disturbances attributed to cortical spreading depolarization (CSD), yet the upstream molecular events that promote or precipitate this phenomenon remain uncertain. Human pharmacological provocation models provide a controlled approach to identifying endogenous signaling pathways capable of triggering aura and thereby clarifying their mechanistic role in migraine pathogenesis. Methods: This systematic review was pre-registered in PROSPERO (ID: CRD420250636266) and conducted in accordance with the Synthesis Without Meta-Analysis (SWiM) guideline. PubMed and Embase were searched from database inception through January 1, 2026, without language restrictions, to identify experimental studies administering pharmacological agents to individuals with migraine with aura under controlled lab conditions. Two reviewers independently performed study selection, data extraction, and methodological assessment. Extracted variables included participant characteristics, study design, pharmacological trigger, dosing protocol, and the incidence, timing, and phenotype of provoked aura and headache. Because of substantial heterogeneity, findings were synthesized qualitatively. Results: Fourteen studies met inclusion criteria, examining seven pharmacological agents: calcitonin gene-related peptide (CGRP), levcromakalim (ATP-sensitive potassium (K ATP ) channels opener), glyceryl trinitrate (GTN), sildenafil, cilostazol, endothelin-1, and histamine. Across studies, aura induction occurred far less frequently than headache induction. CGRP provoked aura in 17 (32%) of 53 participants across three studies, with latencies ranging from 10 to 360 min. Pharmacological opening of vascular K ATP channels by levcromakalim elicited aura in 14 (27%) of 52 participants in randomized crossover trials, with onset between 20 and 120 min. Other agents produced minimal or no aura responses. Conclusions: Human pharmacological provocation provides a reproducible framework for dissecting molecular pathways that can trigger migraine aura. Current evidence implicates CGRP signaling and vascular ATP-sensitive potassium channel activation as the most plausible associated candidate pathways. However, standardized protocols and larger controlled studies are required to confirm these mechanisms and refine experimental models of aura biology. Trial Registration: PROSPERO (ID: CRD420250636266).


  • Open Access

    MIDAS and HIT‐6 Questionnaires Versus Headache Diaries for Monitoring Treatment Response to Erenumab in Migraine: A REFORM Study

    by Janu Thuraiaiyah, Rune Häckert Christensen, Haidar M. Al‐Khazali, Messoud Ashina, Zaza Katsarava, Håkan Ashina

    Background: Headache diaries are the gold standard for assessing preventive migraine treatments but can be burdensome. The Migraine Disability Assessment (MIDAS) and the six‐item Headache Impact Test (HIT‐6) offer alternatives for monitoring treatment response, though their effectiveness in identifying treatment responders is unclear relative to diary‐based measures. This study evaluated how well MIDAS and HIT‐6 distinguish responders from non‐responders to erenumab, and aimed to determine cut‐off scores that best align with a ≥ 50% reduction in monthly migraine days (MMDs). Methods: This prospective, open‐label study enrolled adults with migraine who received 140 mg erenumab for 24 weeks. Treatment response was a ≥ 50% reduction in MMDs based on diary data. MIDAS and HIT‐6 were completed at baseline, Week 12, and Week 24. Discriminative ability and optimal cut‐offs were determined using receiver operating characteristic curve analysis. Results: Among 582 participants, 300 individuals (52%) achieved a ≥ 50% reduction in MMDs. MIDAS and HIT‐6 demonstrated fair discriminative ability in identifying treatment responders, with area under the curve values ranging from 0.71 to 0.77. The optimal MIDAS cut‐offs were either a 16‐point absolute reduction (78% sensitivity, 60% specificity) or a 49% relative reduction (82% sensitivity, 64% specificity). For HIT‐6, optimal thresholds included an 8‐point reduction (53% sensitivity, 84% specificity) or a 12% relative reduction (54% sensitivity, 84% specificity). Sensitivity analyses using alternative response definitions confirmed the primary findings. Conclusions: Although MIDAS and HIT‐6 contribute meaningful information on treatment‐related disability reduction, these retrospective tools lack sufficient precision to replace prospective headache diaries in assessing response to erenumab. Trial Registration: NCT04603976

  • Unveiling Resting-State Functional Connectivity Patterns in Patients With Migraine

    by Roberta Messina, Rune Hackert Christensen, Håkan Ashina, Anjali Sankar, Cedric Gollion, Haidar M. Al-Khazali, Massimo Filippi, Messoud Ashina

    FMRI has proven useful in dissecting the neurobiological underpinnings of migraine. However, the existing evidence is limited by small samples, use of suboptimal statistical thresholds, and different methods of clinical data acquisition. Given these limitations, we hypothesized that a large, well-characterized sample would allow a clearer distinction between resting-state functional connectivity (rs-FC) alterations specific to migraine and those related to migraine subtypes. Adults with migraine and age-matched and sex-matched healthy controls (HCs) underwent a single 3T rs-fMRI scan. We compared rs-FC between migraine and HCs, and across migraine subtypes, using multi-voxel pattern and seed-based analysis. General linear models and analysis of covariance tests with Bonferroni-adjusted cluster-wise family-wise error correction (pFWE-Bonferroni ≤0.001) were applied. rs-FC measures, expressed as Z scores, were also compared across migraine subtypes using general linear models (pBonferroni < 0.05). We analyzed rs-fMRI data from 264 participants with migraine (mean age 42 ± 12 years, 234 women) and 151 HCs (mean age 41 ± 11 years, 130 women). The multi-voxel pattern analysis identified significant rs-FC differences in a cluster within the bilateral middle cingulate cortex when comparing participants with migraine to HCs (pFWE-Bonferroni pFWE-Bonferroni pFWE-Bonferroni = 0.0014) and precuneus (pFWE-Bonferroni pBonferroni pBonferroni <0.001). No significant associations emerged between rs-FC and clinical features in migraine. The identified rs-FC alterations between the middle cingulate cortex and occipital regions might represent a migraine-specific trait, suggesting an integration of nociceptive and visual processing. This discovery provides novel insights into the neurobiological underpinnings of migraine and proposes that altered cingulate-occipital rs-FC might serve as a potential biomarker for migraine.